HEALWELL AI Provides Corporate Update on Capital Allocation Program and Value Creation Strategy
HEALWELL AI Provides Corporate Update on Capital Allocation Program and Value Creation Strategy
- HEALWELL's current goal is to achieve run rate revenues approaching $100 million by the end of the year from today's current run rate of over $65 million. This goal is underpinned by a robust M&A pipeline where there are several advanced subjects including one signed LOI and helps the Company position itself to achieve profitability on an Adjusted EBITDA basis in 2025.
- HEALWELL's four acquisitions to date have positioned the company to unlock the power of health data with artificial intelligence for three key stakeholder groups: (i) Clinicians in healthcare clinics with co-pilot offerings; (ii) Large enterprises such as Canadian Provincial Healthcare systems with Data Interoperability, population health and related services; and (iii) The pharmaceutical industry with a multi-tiered offering that includes scientific research, real-world evidence and clinical trials orchestration services.
- HEALWELL is focused on continuing to grow and build on each of these segments both organically and inorganically using its capital allocation program.
- The Company reiterates its disclosure from July 10th, 2024 that HEALWELL had recently strengthened its balance sheet by removing $15.5 million in total liabilities and had cash in excess of $14.5 million at the end of the second quarter. The Company also disclosed that if all of the Company's in-the-money warrants were to be exercised, HEALWELL's cash balance is expected to grow to an amount in excess of $39 million.
- HEALWELL目前的目标是实现按年计算的营业收入,从今天的超过6500万美元的运营水平到年底接近1亿美元。这一目标得到了强有力的并购管道的支撑,其中包括几个先进的主题,包括已签署的LOI,并帮助公司在2025年实现基于调整后EBITDA的盈利能力。
- HEALWELL迄今为止的四个收购使该公司能够为三个关键利益相关者解锁健康数据与人工智能的力量:(i)医疗诊所中的临床医生提供联合驾驶员服务;(ii)加拿大省级医疗保健系统等大型企业提供数据互操作性、人口健康和相关服务;以及(iii)制药行业提供包括科学研究、真实世界证据和临床试验编排服务在内的多层次服务。
- HEALWELL专注于继续通过其资本配置计划在这些领域中实现有机和非有机的增长和建设。
- 公司重申了2024年7月10日的披露,即HEALWELL最近通过清理总负债15.5百万美元和第二季度末现金超过14.5百万美元的方式加强了其资产负债表。该公司还披露,如果公司所有实际转换的权证都被行使,预计HEALWELL的现金余额将增长到超过3900万美元。
Toronto, Ontario--(Newsfile Corp. - July 23, 2024) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare technology company focused on AI and data science for preventative care, is pleased to provide a corporate update highlighting recent advancement in the Company's acquisition strategy. HEALWELL's current goal is to achieve run rate revenues approaching $100 million by the end of the year, up from today's current run rate of over $65 million. This ambitious target is supported by a robust M&A pipeline, which includes several advanced prospects and one signed LOI and supports the Company's goal of achieving profitability in 2025 on an Adjusted EBITDA basis.
加拿大安大略省--(Newsfile corp. - 2024年7月23日)-HEALWELL人工智能股份有限公司(TSX:AIDX)(OTCQX:HWAIF)("HEALWELL"或"公司"),是一家专注于预防护理人工智能和数据科学的医疗保健技术公司,高兴地提供公司最近在收购策略方面取得的最新进展。 HEALWELL目前的目标是实现按年计算的营业收入,从今天的超过6500万美元的运营水平到年底接近1亿美元。这一雄心勃勃的目标得到了强有力的财务并购管道的支持,这些管道包括多个先进的前景和一个已经签署的LOI,并支持公司在2025年的调整后EBITDA盈利目标。
Dr. Alexander Dobranowski, CEO of HEALWELL commented, "Our confidence in continuing to execute on our M&A pipeline grows every day as HEALWELL is becoming recognized as a high-quality acquirer in the digital health and life sciences marketplace. What is unique about our revenue growth strategy is not only our ability to acquire high quality growth assets but also our ability to integrate these assets with our industry leading artificial intelligence offerings in order to expand margins and accelerate growth."
HEALWELL的首席执行官Alexander Dobranowski博士评论道:“随着HEALWELL在数字医疗和生命科学市场被认为是高质量的收购者,我们继续执行并购管道的信心日益增强。我们收入增长策略的独特之处不仅在于我们收购高质量的增长资产的能力,还在于我们将这些资产与我们行业领先的人工智能产品相结合,以扩展利润率并加速增长。”
Anthony Lam, CFO of HEALWELL commented, "HEALWELL is well positioned to continue its capital allocation program which is very focused on approaching the $100M run-rate figure by the end of the year. This growth also positions the Company to execute on its plans to achieve profitability in fiscal 2025 on an Adjusted EBITDA basis which we also believe is an important component of our value creation strategy and to deliver shareholder value."
HEALWELL首席财务官Anthony Lam评论道:“HEALWELL处于良好的位置,可以通过其资本配置计划实现按年计算的营业收入接近1亿美元的目标。这种增长也使公司能够执行其计划,在2025年的调整后EBITDA基础上实现盈利,我们还认为这是增长价值策略的一个重要组成部分,并提供股东价值。”
HEALWELL's four acquisitions to date, namely Pentavere Research Group Inc. ("Pentavere"), Intrahealth Systems Limited, VeroSource Services Inc. ("VeroSource") and BioPharma Services Inc. ("BioPharma"), have positioned the Company to unlock the power of health data with artificial intelligence for three key stakeholder groups:
HEALWELL迄今为止的四个收购(即Pentavere研究集团公司("Pentavere"),Intrahealth Systems Limited,VeroSource Services Inc。 ("VeroSource")和BioPharma Services Inc。(“BioPharma”))已经为三个关键利益相关者解锁了健康数据和人工智能的力量:
- Clinicians in healthcare clinics with co-pilot offerings. To-date HEALWELL has launched AI enabled clinical co-pilot tools to support providers with Clinical Decision Support in four main domains: rare diseases, chronic diseases, cardiovascular disease and oncology. HEALWELL's strategy is to continue to develop AI enabled co-pilot tools to launch in parallel to the current offerings that are in-production and at scale.
- Large enterprises such as Canadian provincial healthcare systems with data interoperability and related services. Since the acquisition of VeroSource, HEALWELL now offers end-to-end, customizable, cloud-based data interoperability and population health capabilities. These capabilities enable public sector stakeholders to seamlessly access and interact with healthcare data. HEALWELL intends to expand on these offerings to public sector clients across multiple jurisdictions in Canada as it integrates its industry leading AI capabilities into its public sector offerings.
- The pharmaceutical industry with a multi-tiered offering that includes scientific research, real-world evidence and clinical trials orchestration services. With the acquisitions of Pentavere and BioPharama coupled with the capabilities of Khure Health, HEALWELL now has exceptional AI and clinical trial capabilities. These acquisitions have significantly increased the Company's ability to provide both clinical and commercial value for life sciences companies. The addition of BioPharma has expanded HEALWELL's clinical trial offerings to include bioequivalence and early-stage trial services, leveraging HEALWELL's AI capabilities to help identify patients of strong clinical trial eligibility.
- 医疗诊所中的临床医生通过联合飞行员服务迄今为止,HEALWELL已经推出了AI启用的临床联合飞行员工具,以支持提供者在四个主要领域中进行临床决策支持:罕见病、慢性病、心血管疾病和肿瘤学。HEALWELL的策略是继续开发AI启用的联合飞行员工具,并与当前正在生产和扩展规模的product并行推出。
- 加拿大省级医疗保健系统具有数据互操作性和相关服务。自收购VeroSource以来,HEALWELL现在提供端到端、可定制的基于云的数据互操作性和人口健康能力。这些能力使公共部门利益相关者能够无缝地访问和交互医疗保健数据。HEALWELL计划通过将其行业领先的人工智能能力整合到其公共部门提供的产品中,将这些产品扩展到加拿大多个司法辖区的公共部门客户。
- 制药行业,其中包括科学研究、真实世界证据和临床试验编排服务通过Pentavere和BioPharama的收购以及Khure Health的能力,HEALWELL现在拥有非常出色的人工智能和临床试验能力。这些收购使公司显著提高了为生命科学公司提供临床和商业价值的能力。BioPharma的加入扩大了HEALWELL的临床试验服务范围,包括生物等效性和早期试验服务,利用HEALWELL的人工智能能力帮助识别具有强大临床试验资格的患者。
HEALWELL is focused on continuing its growth trajectory by building on each of these segments both organically and inorganically. The Company's capital allocation program will focus on two areas: first, early disease detection AI capabilities; and second, mature operating healthcare software, digital health and research companies that can be enhanced with HELAWELL's tools.
HEALWELL专注于继续通过其资本配置计划在这些领域中实现有机和非有机的增长和建设。公司的资本分配计划将关注两个领域:首先是早期疾病检测AI能力;其次是成熟的运营医疗软件、数字医疗和研究公司,这些公司可以通过HEALWELL的工具进行增强。
HEALWELL is also pleased to re-iterate its disclosure on July 10th, 2024 that the Company had recently strengthened its balance sheet by reducing total liabilities by $15.5M and had cash in excess of $14.5 million at the end of the second quarter. HEALWELL also disclosed that if all of the Company's in-the-money warrants were to be exercised, cash balance is expected to grow to an amount in excess of $39 million. The Company is well positioned to continue its successful capital allocation program and to deliver shareholder value.
HEALWELL也高兴地再次重申其于2024年7月10日披露的内容,即该公司最近通过减少总负债1,550万美元并在第二季度末持有超过1,450万美元的现金来加强其资产负债表。HEALWELL还披露,如果公司所有实际转换的权证都被行使,现金余额预计将增长到超过3900万美元。该公司有能力继续其成功的资本配置计划并提供股东价值。
Non-GAAP financial measures
非GAAP财务指标
The Company uses certain non-GAAP financial measures as supplemental indicators of its financial and operating performance. These non-GAAP financial measures include Adjusted EBITDA. The Company believes this supplementary financial measure reflects the Company's ongoing business in a manner that allows for meaningful analysis of trends in its business.
该公司使用某些非GAAP财务指标作为其财务和营运表现的补充指标。这些非GAAP财务指标包括调整后EBITDA。公司认为,这种补充财务指标以反映公司的经营方式,有助于对其业务趋势进行有意义的分析。
Dr. Alexander Dobranowski
Chief Executive Officer
HEALWELL AI Inc.
首席执行官
首席执行官
关于HEALWELL AI
About HEALWELL AI
HEALWELL是一家专注于AI和数据科学的医疗技术公司,专注于预防保健。其使命是通过疾病的早期识别和发现来改善医疗保健并拯救生命。利用其独有的专有技术,该公司正在开发和商业化先进的临床决策支持系统,可以帮助医疗保健提供者检测罕见和慢性疾病,提高他们的实践效率,最终帮助提高患者的健康结果。HEALWELL正在执行以技术和临床科学能力的发展和收购为中心的战略,这些能力与公司的路线图相互补充。HEALWELL在多伦多证券交易所 (TSX) 上公开交易,股票代码为“AIDX”,在OTC Exchange上下市,股票代码为“HWAIF”。如果想了解更多HEALWELL的信息,请访问
HEALWELL is a healthcare technology company focused on AI and data science for preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary AI technology and competencies which includes data science, electronic health records and clinical research offerings, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol "AIDX" and on the OTC Exchange under the symbol "HWAIF". To learn more about HEALWELL, please visit .
HEALWELL是一家专注于预防保健的医疗技术公司,专注于AI和数据科学。其使命是通过早期疾病识别和检测改善医疗保健,并挽救生命。该公司正在开发和商业化先进的临床决策支持系统,这些系统可以帮助医疗保健提供者检测罕见和慢性疾病,提高其实践的效率,最终帮助改善患者的健康结果。HEALWELL在多伦多证券交易所上市(股票代码“AIDX”),在OTC Exchange上也上市(股票代码“HWAIF”)。要了解有关HEALWELL的更多信息,请访问其网站。
Forward-Looking Statements
前瞻性声明
Certain statements in this press release, constitute "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities laws and are based on assumptions, expectations, estimates and projections as of the date of this press release. Forward-Looking statements in this press release include statements with respect to, among other things, the Company's current and expected run rate revenue, its current M&A pipeline and other future acquisitions by the Company, its expected product offering and customer base, its ability to integrate artificial intelligence technologies into its product offering, and the potential exercise of the Company's outstanding warrants. Forward-Looking statements are often, but not always, identified by words or phrases such as "position", "growth", "future", "opportunity", "potential", "improve", "expect", "intend", "create" or variations of such words and phrases or statements that certain future conditions, actions, events or results "will", "may", "could", "would", "should", "might" or "can" be taken, occur or be achieved, or the negative of any of these terms . Forward-Looking statements are necessarily based upon management's perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by HEALWELL as of the date of such statements, are outside of HEALWELL's control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward-Looking statements contained in this press release are based on various assumptions, including, but not limited to, the following: the Company's ability to successfully integrate recent acquisitions into its organization; the availability of future M&A opportunities and the Company's ability to capitalize on those opportunities; the anticipated timing and quantity of, and demand for, warrant exercises; the effects of competition in the industry; the expected demand for the Company's products and continued profitability of the target companies within its M&A pipeline; trends in customer growth; the stability of general economic and market conditions; currency exchange rates and interest rates; the Company's ability to comply with applicable laws and regulations; the Company's continued compliance with third party intellectual property rights; and that the risk factors noted below, collectively, do not have a material impact on the Company's business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections, or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved.
本新闻稿中的某些陈述构成"前瞻性信息"和"前瞻性声明",依据适用的加拿大证券法,并基于在本新闻稿发布之日的假设、期望、估计和预测。 本新闻稿中的前瞻性声明包括关于公司当前和预期的营运收入、公司当前的M&A流水线和公司未来其他收购、公司预期的产品和客户群、将人工智能技术整合到其产品中的能力以及潜在行权公司未行权认股权证的声明。前瞻性声明通常由“position”、“growth”、“future”、“opportunity”、“potential”、“improve”、“expect”、“intend”、“create”或这类单词或短语形成,或声明某些未来条件、行动、事件或结果“将“、“可能”、“可能”、“应该”、“可能”或“可以”被采取、发生或实现,或者这些术语中任何一个的否定。前瞻性声明必然基于管理层对历史趋势、当前状况和预期未来发展的看法,以及一些特定因素和假设,而这些特定因素和假设,虽然在本声明被认为是合理的,但在HEALWELL公司控制之外,并且天生面临着重大的商业、经济和竞争上的不确定性和意外情况,这可能最终使前瞻性声明完全或部分不正确或不真实。本新闻稿中的前瞻性声明基于各种假设,包括但不限于以下假设:公司能够成功地将最近收购融入其组织中;未来的M&A机会可得到并且公司能够利用这些机会;期权行权的预期时间、数量和需求;行业竞争的影响;公司产品的预期需求和其M&A流水线中目标公司的持续盈利能力;客户增长趋势;一般经济和市场状况的稳定性;货币汇率和利率;公司能够遵守适用法律和法规;公司持续遵守第三方知识产权的权利;以下风险因素作为整体对公司的业务、营运、收入和/或业绩没有重要影响。由于其特性,前瞻性声明面临潜在的一般或特定的固有风险和不确定性,这些风险和不确定性可能导致期望、预测、预测、预测或结论证明不准确,假设可能不正确,并且目标、战略目标和优先事项将无法实现。
Known and unknown risk factors, many of which are beyond the control of HEALWELL, could cause the actual results of HEALWELL to differ materially from the results, performance, achievements, or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled "Risk Factors" in HEALWELL's most recent annual information form dated April 1, 2024, which is available under HEALWELL's SEDAR+ profile at . The risk factors are not intended to represent a complete list of the factors that could affect HEALWELL and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-Looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. HEALWELL disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements.
许多已知和未知的风险因素,许多因素超出了HEALWELL的控制,这些因素可能会导致HEALWELL的实际结果与所述前瞻性陈述所表达或暗示的结果、表现、成就或发展存在实质性差异。这些风险因素包括但不限于在HEALWELL最近的2024年4月1日的最新年度信息表格中讨论的那些因素,该表格可在HEALWELL的SEDA+个人资料中获得。风险因素并非旨在代表可能影响HEALWELL的所有因素的完整列表,请读者谨慎考虑这些和其他因素、不确定性和潜在事件,不要过度依赖前瞻性陈述。无法保证前瞻性陈述将被证明准确,因为实际结果和未来事件可能与这些陈述中预期的有实质性不同。前瞻性陈述是为了提供有关管理层未来的期望和计划的信息而提供的。HEALWELL放弃任何更新或修订任何前瞻性陈述的意向或义务,无论是基于新信息、未来事件或其他原因,或者解释随后实际事件和这些前瞻性陈述之间的任何实质性差异,除非适用法律要求。本新闻稿中包含的所有前瞻性陈述均受这些警示性陈述的限制。
For more information:
欲了解更多信息:
Pardeep S. Sangha
Investor Relations, HEALWELL AI Inc.
Phone: 604-572-6392
ir@healwell.ai
Pardeep S. Sangha
投资者关系,HEALWELL AI Inc。
电话:604-572-6392
ir@healwell.ai